Telepatia has closed a $33 million Series A funding round led by Andreessen Horowitz. The company is building an AI-powered clinical decision platform it calls the AI Doctor, aimed at hospitals across Latin America. The goal is to cut preventable deaths in the region by giving doctors better tools for diagnosis and treatment planning.
Who’s behind the money
Andreessen Horowitz — a16z in shorthand — led the round. The venture firm has been increasing its bets on health-tech in emerging markets, though it doesn’t often back Latin American startups at this stage. Telepatia didn’t disclose whether existing investors also participated or what valuation the round implies. The company now has $33 million in fresh capital to deploy.
What the AI Doctor is supposed to do
Telepatia’s platform is designed to slot into a hospital’s existing workflow. It analyzes patient data — lab results, vital signs, imaging reports — and surfaces recommendations for clinicians. The company says the system is trained on medical literature and local epidemiological data, which matters because disease patterns in Latin America differ from those in the US or Europe. The pitch is straightforward: catch complications early, reduce diagnostic errors, and free up overworked doctors to focus on the sickest patients.
Why Latin America
Preventable death rates remain high across much of Latin America. In many public hospitals, physicians see dozens of patients a day, often with limited access to specialists or up-to-date clinical guidelines. Telepatia argues that an AI layer can act as a force multiplier — giving a general practitioner in a rural clinic something close to the judgment of a specialist. The company hasn’t released data from its own trials yet, but it has been testing the platform in a handful of hospitals in Brazil and Mexico.
What happens next
With the Series A money, Telepatia plans to expand its engineering team and run larger clinical studies. The company also wants to build integrations with electronic health record systems used across the region. Regulatory approval will be a hurdle: health authorities in each country have different rules for software that makes clinical recommendations. Telepatia hasn’t said which market it will target first for formal clearance.
